Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15018595 | 1.00 | SMYD2 (0.36) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL15018571 | 0.80 | SMYD2 (0.39) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL16259096 | 0.80 | SMYD2 (0.39) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL17539093 | 0.77 | TOP2A (0.33) | — | |
| SCHEMBL22470033 | 0.70 | SMYD2 (0.44) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL31058599 | 0.69 | SMYD2 (0.43) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL31058601 | 0.68 | SMYD2 (0.43) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL599980 | 0.67 | SMYD2 (0.48) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL25062337 | 0.66 | SMYD2 (0.41) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL31645130 | 0.66 | SMYD2 (0.41) | SMYD2CYP3A4HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9403763-B2 | CD4-mimetic inhibitors of HIV-1 entry and methods of use thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-08-02 | — | — | US | disclosed |
| US-20140350113-A1 | CD4-MIMETIC INHIBITORS OF HIV-1 ENTRY AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140350113-A1 | CD4-MIMETIC INHIBITORS OF HIV-1 ENTRY AND METHODS OF USE THEREOF | CD4, CD14, CCR5 | SMYD2 4853/4885CYP3A4 1051/4885HTT 2660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.